Scholarlink

<p>A series of 21 indolyl oxoacetamide analogues with benzyloxy-substituents were designed, synthesized and characterized using <sup>1</sup>H NMR (Nuclear Magnetic Resonance), <sup>13</sup>C NMR, and HRMS (High Resolution Mass Spectrometry) analysis. All the analogues were tested for inhibitory activity against pancreatic lipase. Two analogues, <b>9f</b> and <b>10f</b>, exhibited significant activity (IC<sub>50</sub> of 2.89 and 2.50 µM, respectively), comparable to the standard drug, orlistat (IC<sub>50</sub> = 0.99 µM). The potent analogues <b>10f</b> and <b>9f</b> exhibited significant binding affinity for pancreatic lipase (-170.222&#xa0;kcal mol<sup>− 1</sup> and − 153.547&#xa0;kcal mol<sup>− 1</sup>). Additionally, both the potent analogues exhibited crucial interaction with Ser 152 and His 263 residues in the PL active site via hydrogen bonding. Molecular dynamics (MD) simulation was performed on the ligand-receptor complex of potent analogue (<b>10f</b>) for 200 ns. The molecule was stabilized by extending the π-π interactions with Phe 77 and Phe 215 of the active site lid domain due to benzyloxy substitution. Toxicity profile prediction indicated that all the analogues were non-hepatotoxic, unlike orlistat.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Synthesis, Molecular Modelling and Biological Evaluation of Novel Benzyloxy Substituted Indolyl Oxoacetamides as Potent Pancreatic Lipase Inhibitors

  • 期刊论文

  • 发表日期：

    2025年8月8日

查看全文
  • S. N. C. Sridhar,
  • Utkarsh A. Jagtap,
  • Vijeta Kumari,
  • P. S. Dileep,
  • Paul Atish Tulshiram

摘要

A series of 21 indolyl oxoacetamide analogues with benzyloxy-substituents were designed, synthesized and characterized using 1H NMR (Nuclear Magnetic Resonance), 13C NMR, and HRMS (High Resolution Mass Spectrometry) analysis. All the analogues were tested for inhibitory activity against pancreatic lipase. Two analogues, 9f and 10f, exhibited significant activity (IC50 of 2.89 and 2.50 µM, respectively), comparable to the standard drug, orlistat (IC50 = 0.99 µM). The potent analogues 10f and 9f exhibited significant binding affinity for pancreatic lipase (-170.222 kcal mol− 1 and − 153.547 kcal mol− 1). Additionally, both the potent analogues exhibited crucial interaction with Ser 152 and His 263 residues in the PL active site via hydrogen bonding. Molecular dynamics (MD) simulation was performed on the ligand-receptor complex of potent analogue (10f) for 200 ns. The molecule was stabilized by extending the π-π interactions with Phe 77 and Phe 215 of the active site lid domain due to benzyloxy substitution. Toxicity profile prediction indicated that all the analogues were non-hepatotoxic, unlike orlistat.

Graphical Abstract